Published in final edited form as:

Metabolism. 2011 August ; 60(8): 1178–1185. doi:10.1016/j.metabol.2010.12.014.

Bioactive Androgens and Glucuronidated Androgen Metabolites are Associated with Subcutaneous and Ectopic Skeletal Muscle Adiposity among Older Black Men

Iva Miljkovic, MD, PhD¹, Jane A Cauley, DrPH¹, Amy S Dressen, MPH, Christopher L Gordon, PhD², Bret H Goodpaster, PhD³, Lewis H Kuller, MD, DrPH¹, Clareann H Bunker, PhD¹, Alan L Patrick, MD, FRCP⁴, Victor W Wheeler, MBBS, MRCOG⁴, Eric S Orwoll, MD⁵, and Joseph M Zmuda, PhD¹

¹ Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA

² Radiology, McMaster University, Hamilton, Ontario, Canada, L8N-3Z5

³ Endocrinology and Metabolism, University of Pittsburgh's Department of Medicine, Pittsburgh, PA 15261, USA

⁴ Tobago Health Studies Office, Scarborough, Tobago, Trinidad & Tobago

⁵ Oregon Health and Science University, Portland, OR, USA

Abstract

Aging is associated with declining serum levels of androgenic hormones and with increased skeletal muscle fat infiltration, an emerging risk factor for type 2 diabetes mellitus (T2DM). Androgens regulate fat mass and glucose homeostasis, but the effect of androgenic hormones on skeletal muscle fat infiltration is largely unknown. Thus, the aim of the current study was to examine the association of serum androgens and their precursors and metabolites with skeletal muscle fat infiltration and T2DM in a black male population group at high risk of T2DM. Serum androgens, estrogens, and androgen precursors and metabolites were measured using mass spectrometry, and calf skeletal muscle fat distribution [subcutaneous and intermuscular fat; skeletal muscle density] were measured using quantitative computed tomography in 472 Afro-Caribbean men aged 65 and older. Bioactive androgens, testosterone, free testosterone and dihydrotestosterone, were associated with less skeletal muscle fat infiltration ($r=-0.14$ to -0.18 , $P<0.05$) and increased skeletal muscle density ($r=0.10$ to 0.14 , $P<0.05$), independent of total

Corresponding Author: Iva Miljkovic, MD, PhD; Department of Epidemiology, Center for Aging and Population Health, 130 North Bellefield Avenue, Room 542, Pittsburgh, PA 15261; Phone: (+1) 412-383-1894; miljkovici@edc.pitt.edu.

Conflict of interest: CL Gordon has received a consulting fee for reading of the pQCT scans. Other authors have nothing to disclose.

Disclosure statement: CL Gordon has received a consulting fee for reading of the pQCT scans. Other authors have nothing to disclose.

Author contributions: The authors' responsibilities were as follows—I. Miljkovic: project development, writing of the manuscript, and primary responsibility for the final content; J.A. Cauley, B.H. Goodpaster, L.H. Kuller, and E.S. Orwoll: assistance with data interpretation; A.S. Dressen: statistical analyses; C.L. Gordon: analyses of all pQCT scans and data interpretation; C.H. Bunker, A.L. Patrick, and V.W. Wheeler, Co-Principal Investigators of the Tobago Health Study: study design and supervision of data collection; J.M. Zmuda, a Co-Principal Investigator of the Tobago Health Study: study design, guidance for project development, and data collection for this manuscript; and all authors: significant suggestions, advice, and consultation on the preparation of the manuscript. All authors read and approved the final manuscript.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

adiposity. Additionally, glucuronidated androgen metabolites were associated with less subcutaneous fat ($r=-0.11$ to -0.15 , $P<0.05$). Multivariate logistic regression analysis identified an increased level of 3α -diol-3 glucuronide ($OR=1.38$, $P<0.01$) and a decreased level of dihydrotestosterone ($OR=0.66$, $P<0.01$) to be significantly associated with T2DM. Our findings suggest that in elderly black men, independent of total adiposity, bioactive androgens and glucuronidated androgen metabolites may play previously unrecognized role in skeletal muscle fat distribution. Longitudinal studies are needed to further evaluate the relationship between androgens and androgen metabolites with changes in skeletal muscle fat distribution with aging and the incidence of T2DM.

Keywords

sex hormones; androgen; skeletal muscle; adipose tissue; type 2 diabetes mellitus; aging; black men

Introduction

Black populations have a greater propensity to develop obesity and type 2 diabetes mellitus (T2DM) than other ethnic groups [1]. Although, high rates of T2DM in blacks are often attributed to their high rates of obesity, differences in total and central obesity fail to explain differences in T2DM rates [2–8], especially among men [1]. Emerging evidence indicates that insulin resistance and T2DM may be a result of the imbalance of fat distribution in non-adipose tissues, such as skeletal muscle [9], but the nature of these relationships remains to be clarified and causality continues to be debated. There is also some evidence that ectopic skeletal muscle fat infiltration, or myosteatosis [9], increases with aging and is greater in black than in white men at all levels of total adiposity [10].

Androgens decline with aging [11], and play an important role in the regulation of overall body fat mass and fat distribution [12], as well as glucose and insulin homeostasis [13]. Although the inverse association of androgens with general and central adiposity [14], and with T2DM [15] is well documented in white men, studies have not assessed relationships with myosteatosis, an emerging risk factors for T2DM, or the relationship of androgen precursors and metabolites with adiposity and T2DM, particularly among black men. Androgens are secreted primarily from the testes, but can also be synthesized and degraded in peripheral target tissues, in the same tissues in which they exert their action. This somewhat limits the use of serum levels of androgens, suggesting that androgen metabolites may reflect intracellular androgen levels beyond serum androgen levels [16], and may be better markers of androgen activity in peripheral tissues [17].

The aim of the current study is to examine the association of serum androgens and their precursors and metabolites with myosteatosis and T2DM in a unique older Afro-Caribbean male population, with low levels of total adiposity, but high risk of T2DM [10]. We hypothesized that higher levels of androgenic hormones would be associated with less skeletal muscle fat infiltration and with lower T2DM risk, independent of total adiposity.

Materials and Methods

Study Population

Between 1997 and 2003, 3170 previously unscreened men were recruited for a population-based prostate cancer screening study on the Caribbean Island of Tobago, Trinidad and Tobago [18]. To be eligible, men had to be ambulatory, non-institutionalized and not terminally ill. Recruitment for the survey was accomplished by flyers, public service

announcements, posters, informing health care workers at local hospital and health centers, and word of mouth. Approximately 60% of all age-eligible men on the island participated and participation was similar across the island Parishes. All men were invited to participate in a follow-up clinic exam between 2004 and 2007 and 2,031 men in the cohort (70% of survivors) and 451 new participants completed the visit. There were 618 Afro-Caribbean (all 4 grandparents of African ancestry) men aged 65 and older who completed the follow-up visit. Serum sex steroid hormone measurements were completed in a random subset of 500 men aged 65 years. 472 men had complete data on anthropometrics, peripheral quantitative computed tomography (pQCT) measured skeletal muscle composition, demographic information, and medical history. Written informed consent was obtained from every participant, using forms and procedures approved by the Tobago Ministry of Health and Social Services and University of Pittsburgh Institutional Review Boards.

Hormone Assays

Blood samples were obtained in the morning (between 7–9 am) by venipuncture after a 12-hour fast. Whole blood was drawn into sterile red top (serum) tubes, stood at room temperature for a minimum of 20 minutes to clot before centrifugation, and the serum aliquoted into 1.0 mL cryovials and stored at -80°C until assays were completed. Hormone assays were completed using a validated and highly-specific gas chromatography/liquid chromatography/mass spectrometry (GC/LC/MS) technique to measure fasting serum levels of unconjugated sex steroid precursors (DHEA, DHEAS, 4-dione, 5-diol), sex steroids (T, DHT, E1, E2) and conjugated androgen metabolites (3G, 17G, ADTG) under Good Laboratory Practices. Details of the laboratory methods have been described [17,19]. Sex hormone binding globulin (SHBG) assays were completed with an Immulite Analyzer with chemiluminescent substrate (Diagnostic Products Corp., Los Angeles, California, USA). Free fractions of testosterone and estradiol were calculated using the method described by Sodergard [20]. The coefficients of variation (CV) for all sex hormones are listed in Supplementary Table 1.

Peripheral Quantitative Computed Tomography (pQCT)

A peripheral quantitative computerized tomography (pQCT) scan of the calf was performed using the Stratec XCT-2000 in order to evaluate skeletal muscle fat and muscle cross-sectional areas. Scans were obtained at 66% of the calf length, proximal to the terminal end of the calf. This site was chosen as it is the region of the lower leg with the largest circumference of the calf with very little variability across individuals [21]. Different tissues in the analyses were separated according to different density thresholds, using the “soft tissue” algorithm. Based on the calibration, fat, muscle, and cortical bone are measured with mineral equivalent densities of 0, 80, and 1200 mg/cm^3 , respectively. Therefore, changes in muscle tissue to fat like tissue will be detected as a shift in mineral equivalent density of the muscle from 80 to 0 mg/cm^3 . Images of the cross-sectional area of skeletal muscle and fat were analyzed using the Stratec analysis software version 5.5D (Orthometrix, Inc., White Plains, NY). To maintain consistency, all images were analyzed by a single investigator (CL Gordon). There are two fat depots within skeletal muscle: fat infiltration within myocytes (intramyocellular fat) and visible fat within the fascia surrounding skeletal muscle (intermuscular fat). We obtained measures of the total fat area (mm^2), subcutaneous fat area (mm^2), intermuscular fat area (mm^2), skeletal muscle area (mm^2), and muscle density (mg/cm^3). Muscle density is a valid measure of fat infiltration within the skeletal muscle and reflects the fat content of skeletal muscle such that greater fat infiltration is associated with lower muscle density [22]. The CVs for pQCT skeletal muscle composition traits are listed in Supplementary Table 1.

Other Measures

Standing height was measured to the nearest 0.1 cm using a wall-mounted stadiometer. Body weight was recorded to the nearest 0.1 kg without shoes on a balance beam scale. Body mass index was calculated from body weight and standing height (kg/m^2). Waist circumference was measured at the narrowest point of the waist using an inelastic fiberglass tape. If there was no narrowest point, waist circumference was measured at the umbilicus. Total body fat was measured by dual-energy X-ray absorptiometry (DXA) using a Hologic QDR 4500W densitometer (Hologic Inc., Bedford MA). Scans were analyzed with QDR software version 8.26a. Information on medical conditions and medication use, were also assessed using interviewer administered questionnaires. No participant used oral corticosteroids. Fasting serum glucose was measured using an enzymatic procedure [23] and insulin was measured using an RIA procedure developed by Linco Research, Inc. [22]. Their CVs are listed in Supplementary Table 1. The degree of insulin resistance was estimated by HOMA according to the method described by Matthews et al [24]. T2DM was defined as fasting serum glucose $\geq 126\text{mg/dl}$ or currently taking anti-diabetic medication. Obesity was defined as BMI $\geq 30\text{ kg/m}^2$.

Statistical Analyses

The distributions of all the continuous measures were first assessed for departures from normality. DHEA-S, DHT, ADT, 3G, 17G and intermuscular fat were log transformed, whereas subcutaneous fat was square root transformed before statistical analysis. The association between serum sex hormones and adiposity and T2DM-related measures was determined using spearman correlation analysis. Spearman correlations among all sex steroid variables and among all adiposity and metabolic traits were calculated and are shown in Supplementary Tables 2 and 3. Analyses of insulin, glucose and HOMA traits were conducted after excluding individuals with fasting serum glucose $\geq 126\text{mg/dl}$ or those currently taking anti-diabetic medication as we were interested in associations among normoglycemic individuals. Because of their presumed relationships with the components of skeletal muscle composition and our focus on skeletal muscle fat infiltration independent of age, body size, total adiposity and skeletal muscle, age, height, DXA total body fat and skeletal muscle were evaluated as covariates. Logistic regression was used to examine the relationships between sex hormones and adiposity measures with T2DM, and are presented in age-adjusted, age- and BMI-adjusted, and age- and waist- adjusted models. The odds ratio (OR) and 95% confidence intervals are presented by one standard deviation increase for all continuous variables. All variables with p value < 0.05 in age-adjusted models were further considered for inclusion in the multiple linear regression analysis using a backward procedure to determine the independent associations with T2DM. We examined multi-collinearity prior to the multiple linear regression analysis by assessing the variance inflation factor (VIF). We included one total or central adiposity measure (BMI, waist or DXA total body fat %) with no multi-collinearity along with sex hormones and pQCT skeletal muscle composition variables in the backward logistic regression model. The model with the best goodness-of-fit is presented as the final model. The Statistical Analysis System (SAS, version 9.1.2.; SAS Institute, Cary, NC) and the Statistical Package for the Social Sciences (SPSS, version 17; Chicago, IL) were used for statistical analysis.

Results

Characteristics of Participants

The mean age of the men was 72 ± 6 years (range, 65–92 years; Table 1). On average participants were moderately overweight as measured by BMI (mean BMI $26.8 \pm 4.1\text{ kg/m}^2$), but had relatively low total body fat (mean DXA total body fat percent $21.7 \pm 5.7\%$). Approximately 19% of the men were obese and 32% had T2DM.

Association of Sex Steroid Hormones with Adiposity, Skeletal Muscle Composition and T2DM-related Measures among Older Black Men

SHBG, androgen precursors 4-DIONE and 5-DIOL, all bioactive androgens (T, Free T and DHT) and the androgen metabolite, ADT, were inversely associated with BMI, waist circumference, DXA total body fat % and pQCT total fat area in the calf ($r = -0.11$ to -0.42 , all $P < 0.05$, Table 2). All three bioactive androgens were negatively associated with intermuscular fat ($r = -0.14$ to -0.18 , $P < 0.01$, Table 2), whereas free T, DHT, ADT, and 17G were positively associated with muscle density ($r = 0.10$ to 0.17 , $P < 0.05$, Table 2). The glucuronidated androgen metabolites, ADTG, 3G and 17G, were inversely associated with subcutaneous fat ($r = -0.11$ to -0.15 , $P < 0.05$, Table 2). We also found that SHBG was positively associated with skeletal muscle ($r = 0.10$, $P < 0.05$, Table 2), whereas ADT was negatively associated with skeletal muscle ($r = -0.16$, $P < 0.01$, Table 2). All findings related to skeletal muscle composition were independent of age, height and total adiposity. We found no association between serum estrogen concentrations and androgen precursors DHEA and DHEAS with any adiposity measures (data not shown). None of the androgens or estrogens was associated with fasting glucose levels (data not shown). SHBG, T and DHT were negatively correlated with insulin ($r = -0.21$, $r = -0.16$ and $r = -0.15$, respectively, all $p < 0.05$) and the HOMA index after adjusting for age and BMI (data not shown).

The Relationship of Sex Steroid Hormones, Adiposity and Skeletal Muscle Composition Measures with T2DM among Older Black Men

We further quantified the relationship of serum sex steroid hormones, adiposity and skeletal muscle composition measures with T2DM adjusting for age, age and BMI, or age and waist circumference (Table 3). Serum concentrations of 5-DIOL, and all three bioactive androgens (T, FT and DHT) were inversely associated with T2DM, whereas serum levels of ADTG and 3G were positively associated with T2DM in all models. Subcutaneous fat and skeletal muscle were inversely associated with T2DM, whereas intermuscular fat was positively associated with T2DM only in the age-adjusted model.

We further tested the independent associations of these measures with T2DM using backward multivariate logistic regression analysis. The model with the best goodness-of-fit is presented as the final model (Table 3). DHT, subcutaneous fat and skeletal muscle remained inversely correlated with T2DM, whereas 3G and waist circumference remained positively correlated with T2DM.

Discussion

We examined the association of serum androgens and their precursors and metabolites with ectopic skeletal muscle fat infiltration and indices of T2DM risk in a black population at high risk of T2DM [25]. Our findings suggest that there is an inverse association between fat infiltration in skeletal muscle, fasting insulin and insulin resistance, and bioactive androgens, independent of total adiposity. Moreover, in multivariable models higher dihydrotestosterone was independently associated with a lower prevalence of T2DM. We also confirmed previous work in white men and young black men [14,26–30], and extended the existing literature by reporting that higher levels of bioactive androgens are associated with lower total and central adiposity among older black men.

The data regarding androgenic hormone effects on fat infiltration in skeletal muscle are very limited. Previous study among 54 healthy young eugonadal white men has reported that testosterone administration decreases ectopic skeletal muscle fat infiltration [31]. Our results raise the possibility that lower androgenic hormone levels may promote increased fat

infiltration in skeletal muscle and insulin resistance. However, it is also possible that increased skeletal muscle fat infiltration may have an effect on androgen metabolism and/or androgen production, and such hypotheses should be tested in future longitudinal studies in this population. The presence of androgens and androgen receptors in fat is well established [32], and an inverse association between serum testosterone concentrations and total and central body fat in men is well known [14,29,33].

With the exception of free testosterone in our study, all bioactive androgens were inversely associated with fasting insulin and insulin resistance. Additionally, DHT was independently associated with a decreased prevalence of T2DM. A meta-analysis of 43 studies and 6427 men, and several large studies in African-American men, suggest a strong link between low testosterone levels and hyperglycemia, insulin resistance and T2DM [13,15,34]. Whether insulin and insulin resistance impair testosterone synthesis, or reduced testosterone increases hyperinsulinaemia and insulin resistance is still uncertain. A few longitudinal studies, such as the Massachusetts Male Aging Study [35] and the Rancho Bernardo Study [36], have reported a positive association between low baseline bioactive androgens and future onset of T2DM among men, but additional longitudinal studies are needed in large multi-ethnic cohorts. Although epidemiological evidence suggests a consistent association between hyperglycemia, insulin resistance, T2DM and low testosterone levels, the mechanism behind these associations are still unclear. It is possible that the Leydig cell dysfunction, caused by insulin resistance mediated changes in the production of hormones and cytokines locally in the target tissue and in adipose tissue, is responsible for low testosterone levels observed in insulin resistance and T2DM [37]. Androgens may also influence insulin resistance via activation of peroxisome proliferator-activated receptor α [38] and by reducing serum levels of tumor necrosis factor α [39]. Nonetheless, some have suggested that androgen deficiency is a consequence of a poor metabolic status in diseases such as obesity and T2DM rather than a direct cause of these conditions [40]. It is possible that the relationship between lower androgen levels and insulin resistance is mediated by total and central adiposity as was previously shown in non-diabetic white men [41]. However, in our analyses we found that the association between DHT and T2DM was independent of overall adiposity, waist circumference and subcutaneous fat.

We further found associations between androgen metabolites and adiposity. In particular, 17G, and to some extent 3G were positively related to total and central adiposity and inversely to subcutaneous fat. Further, 17G was associated with greater skeletal muscle density. There are limited data on the association of androgen metabolites and adiposity. The role and importance of glucuronidated metabolites is still controversial. Previous studies have reported a positive association of 3G with total and visceral fat in white men [42], an increase in 3G levels with weight gain [43], and a decrease in 3G levels with weight loss in young white men [44]. However, comparison of our results with these previous studies is difficult because glucuronidated androgen metabolites were derived using different methods, such as RIA, that could not separate 3G and 17G. Using liquid chromatographic-tandem mass spectrometry Vandeput found a positive association between 17G and central adiposity in white men [30]. Our work extends these observations to black men. Vandeput et al. also reported no association of 3G with body fat in white men and hypothesized that fat tissue is mainly involved in 17-glucuronidation of 3α -diol, whereas 3-glucuronidation of 3α -diol is mainly dependent on glucuronidation in other tissues [30]. The physiological role and importance of glucuronidated metabolites is still controversial. Increased fat may lead to a greater capacity for 17-glucuronidation of 3α -diol, and subsequently to increased levels of 17G. However, it is possible that glucuronidated metabolites are directly involved in the regulation of fat tissue, but a probable causal link and cellular mechanisms remain to be tested and established in future studies.

We confirmed an association between SHBG, adiposity and insulin resistance [45,46]. Some have hypothesized that the association between bioactive androgens and T2DM is mediated through SHBG [47]. A previous study has shown that insulin may directly inhibit SHBG secretion from hepatoma cells in vitro [48]. A recent study of 40 to 70 year-old predominantly white men examined the association of SHBG and T2DM after adjusting for total and free testosterone levels [47]. Although we found SHBG to be associated with insulin and insulin resistance, after adjusting for waist circumference and DHT androgens in our sample, we found no association between SHBG and T2DM, suggesting that among black men the association between SHBG and insulin and insulin resistance may be mediated through central adiposity and DHT.

We found no association between serum estrogens and any of the adiposity or T2DM related measures. Some studies suggest that in obese men, higher estradiol levels, generated by aromatization of androgens in peripheral fat tissues [49], suppresses gonadotropic hormone levels and thus testicular testosterone production [50]. Estradiol was positively associated with adiposity [51] and T2DM [15] in men in some studies, whereas in others no association between estradiol and obesity was observed [52]. None of these past studies examined the relationships between estrogen levels and skeletal muscle fat infiltration.

The potential mechanisms responsible for androgen effects on fat infiltration in skeletal muscle are unknown and require further investigation. Testosterone inhibits the activity of lipoprotein lipase, the main enzymatic regulator of triglyceride uptake in fat [53] resulting in inhibition of lipid uptake and increased lipid mobilization [54]. Androgens also inhibit the differentiation of human mesenchymal pluripotent stem cells and preadipocytes into adipocytes and stimulate the commitment into the myogenic lines via the androgen receptor [55]. Whether these mechanisms mediate androgenic hormone effects on skeletal muscle fat infiltration is unclear and will require further research.

We found subcutaneous fat to be independently, inversely associated with T2DM. Previous studies have shown that independent of overall adiposity, lower subcutaneous fat is associated with glucose abnormalities, insulin resistance and T2DM [25,56]. Some have hypothesized that in addition to impaired lipid storage and utilization, an overflow of fat storage in the inter- and intra- muscular compartments may be due to a defect in the ability of subcutaneous fat to store excess fatty acids [57]. Previous studies have suggested that increased accumulation of skeletal muscle fat may impair the insulin receptor substrate 1/ phosphatidylinositol 3-kinase pathway and growth-factor-regulated protein kinase B pathway of insulin signaling [58]. Others have suggested that increased accumulation of lipid intermediates, such as diacylglycerol, long-chain fatty acyl-CoA species, ceramides, and oxidized lipid mediators, due to increased accumulation of fat in myocytes, may be responsible for suppressing insulin signaling [59]. Others have proposed that the link between myosteatosis and T2DM may be through impaired secretion of cytokines [60]. However, all previous studies have been cross-sectional, and a causal link between myosteatosis, subcutaneous fat, and T2DM remains to be established in longitudinal studies.

The present study has several potential limitations. First, we assessed the associations between sex hormones and adiposity and T2DM among older black men which may limit the generalizability of our findings. Second, it is important to emphasize that T2DM was ascertained without an oral glucose tolerance test and some misclassification was likely to have occurred. Finally, our study was cross-sectional in design and a longitudinal study would better delineate the effects of sex hormones on fat infiltration in skeletal muscle and T2DM risk.

In conclusion, this report is the first to investigate the association between sex steroid hormones and metabolites with skeletal muscle fat infiltration measured by QCT. Our findings support the notion that bioactive androgens and glucuronidated androgen metabolites may play previously unrecognized role in skeletal muscle fat distribution, suggestive of possible another link between androgens and T2DM. Additionally, our findings suggest an independent association of bioactive androgens, glucuronidated androgen metabolites, and subcutaneous fat around skeletal muscle with T2DM. Therefore, longitudinal studies are critically needed to evaluate the relationship between androgens and metabolites with changes in skeletal muscle fat distribution with aging, and further test if androgen metabolites and/or skeletal muscle fat distribution are related to the incidence of T2DM in high-risk Black male populations. Such studies may provide new insight into the pathophysiology of T2DM and suggest new therapeutic targets for the treatment and prevention of insulin resistance and T2DM.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Dr. Miljkovic is supported by the Mentored Research Scientist Development Award from the National Institute of Diabetes and Digestive and Kidney Diseases (grant K01DK083029). The Tobago Health Study is supported by funding or in-kind services from the Division of Health and Social Services and Tobago House of Assembly and by funding from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant R01AR049747). The authors would like to thank the study participants and all supporting staff.

List of Sex Hormone Abbreviations

ADT	Androsterone
ADT-G	Androsterone-glucuronide
DHEA	Dehydroepiandrosterone
DHEA-S	Dehydroepiandrosterone sulfate
DHT	Dihydrotestosterone
E1	Estrone
E2	Estradiol
FT	Free Testosterone
SHBG	Sex hormone binding globulin
T	Testosterone
3G	Androstane-3 α ,17 β -diol-3-glucuronide
17G	Androstane-3 α ,17 β -diol-17-glucuronide
4-Dione	Androstenedione
5-Diol	Androst-5-ene-3 β , 17 β -diol

References

1. Brancati FL, Kao WH, Folsom AR, et al. Incident type 2 diabetes mellitus in African American and white adults: the Atherosclerosis Risk in Communities Study. *Jama*. 2000; 283(17):2253–9. [PubMed: 10807384]

2. Marcus MA, Murphy L, Pi-Sunyer FX, et al. Insulin sensitivity and serum triglyceride level in obese white and black women: relationship to visceral and truncal subcutaneous fat. *Metabolism*. 1999; 48(2):194–9. [PubMed: 10024081]
3. Ryan AS, Nicklas BJ, Berman DM. Racial differences in insulin resistance and mid-thigh fat deposition in postmenopausal women. *Obes Res*. 2002; 10(5):336–44. [PubMed: 12006632]
4. Despres JP, Couillard C, Gagnon J, et al. Race, visceral adipose tissue, plasma lipids, and lipoprotein lipase activity in men and women: the Health, Risk Factors, Exercise Training, and Genetics (HERITAGE) family study. *Arterioscler Thromb Vasc Biol*. 2000; 20(8):1932–8. [PubMed: 10938014]
5. Conway JM, Yanovski SZ, Avila NA, et al. Visceral adipose tissue differences in black and white women. *Am J Clin Nutr*. 1995; 61(4):765–71. [PubMed: 7702017]
6. Hill JO, Sidney S, Lewis CE, et al. Racial differences in amounts of visceral adipose tissue in young adults: the CARDIA (Coronary Artery Risk Development in Young Adults) study. *Am J Clin Nutr*. 1999; 69(3):381–7. [PubMed: 10075320]
7. Lovejoy JC, de la Bretonne JA, Klemperer M, et al. Abdominal fat distribution and metabolic risk factors: effects of race. *Metabolism*. 1996; 45(9):1119–24. [PubMed: 8781299]
8. Ding J, Visser M, Kritchevsky SB, et al. The association of regional fat depots with hypertension in older persons of white and African American ethnicity. *Am J Hypertens*. 2004; 17(10):971–6. [PubMed: 15485762]
9. Miljkovic I, Zmuda JM. Epidemiology of myosteatosis. *Curr Opin Clin Nutr Metab Care*. 2010; 13(3):260–4. [PubMed: 20179586]
10. Miljkovic I, Cauley JA, Petit MA, et al. Greater adipose tissue infiltration in skeletal muscle among older men of African ancestry. *J Clin Endocrinol Metab*. 2009; 94(8):2735–42. [PubMed: 19454588]
11. Rodriguez A, Muller DC, Metter EJ, et al. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. *J Clin Endocrinol Metab*. 2007; 92(9):3568–72. [PubMed: 17595254]
12. Blouin K, Veilleux A, Luu-The V, et al. Androgen metabolism in adipose tissue: recent advances. *Mol Cell Endocrinol*. 2009; 301(1–2):97–103. [PubMed: 19022338]
13. Traish AM, Saad F, Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. *J Androl*. 2009; 30(1):23–32. [PubMed: 18772488]
14. Gapstur SM, Gann PH, Kopp P, et al. Serum androgen concentrations in young men: a longitudinal analysis of associations with age, obesity, and race. The CARDIA male hormone study. *Cancer Epidemiol Biomarkers Prev*. 2002; 11(10 Pt 1):1041–7. [PubMed: 12376505]
15. Ding EL, Song Y, Malik VS, et al. Sex Differences of Endogenous Sex Hormones and Risk of Type 2 Diabetes: A Systematic Review and Meta-analysis. *JAMA*. 2006; 295(11):1288–1299. [PubMed: 16537739]
16. Labrie F. Intracrinology. *Mol Cell Endocrinol*. 1991; 78(3):C113–8. [PubMed: 1838082]
17. Labrie F, Belanger A, Belanger P, et al. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. *J Steroid Biochem Mol Biol*. 2006; 99(4–5):182–8. [PubMed: 16621522]
18. Bunker CH, Patrick AL, Konety BR, et al. High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey. *Cancer Epidemiol Biomarkers Prev*. 2002; 11(8):726–9. [PubMed: 12163325]
19. Labrie F, Cusan L, Gomez JL, et al. Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer. *J Steroid Biochem Mol Biol*. 2009; 113(1–2):52–6. [PubMed: 19073258]
20. Sodergard R, Backstrom T, Shanbhag V, et al. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. *J Steroid Biochem*. 1982; 16(6):801–10. [PubMed: 7202083]
21. Simonsick EM, Maffeo CE, Rogers SK, et al. Methodology and feasibility of a home-based examination in disabled older women: the Women's Health and Aging Study. *J Gerontol A Biol Sci Med Sci*. 1997; 52(5):M264–74. [PubMed: 9310080]

22. Goodpaster BH, Kelley DE, Thaete FL, et al. Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. *J Appl Physiol.* 2000; 89(1):104–10. [PubMed: 10904041]
23. Bondar RJ, Mead DC. Evaluation of glucose-6-phosphate dehydrogenase from *Leuconostoc mesenteroides* in the hexokinase method for determining glucose in serum. *Clin Chem.* 1974; 20(5):586–90. [PubMed: 4363766]
24. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia.* 1985; 28(7):412–9. [PubMed: 3899825]
25. Miljkovic-Gacic I, Gordon CL, Goodpaster BH, et al. Adipose tissue infiltration in skeletal muscle: age patterns and association with diabetes among men of African ancestry. *Am J Clin Nutr.* 2008; 87(6):1590–5. [PubMed: 18541544]
26. Haffner SM, Karhapa P, Mykkanen L, et al. Insulin resistance, body fat distribution, and sex hormones in men. *Diabetes.* 1994; 43(2):212–9. [PubMed: 8288045]
27. Haffner SM, Valdez RA, Stern MP, et al. Obesity, body fat distribution and sex hormones in men. *Int J Obes Relat Metab Disord.* 1993; 17(11):643–9. [PubMed: 8281222]
28. Osuna JA, Gomez-Perez R, Arata-Bellabarba G, et al. Relationship between BMI, total testosterone, sex hormone-binding-globulin, leptin, insulin and insulin resistance in obese men. *Arch Androl.* 2006; 52(5):355–61. [PubMed: 16873135]
29. Seidell JC, Bjorntorp P, Sjostrom L, et al. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. *Metabolism.* 1990; 39(9):897–901. [PubMed: 2202881]
30. Vandenput L, Mellstrom D, Lorentzon M, et al. Androgens and glucuronidated androgen metabolites are associated with metabolic risk factors in men. *J Clin Endocrinol Metab.* 2007; 92(11):4130–7. [PubMed: 17711928]
31. Woodhouse LJ, Gupta N, Bhasin M, et al. Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men. *J Clin Endocrinol Metab.* 2004; 89(2):718–26. [PubMed: 14764787]
32. Joyner J, Hutley L, Cameron D. Intrinsic regional differences in androgen receptors and dihydrotestosterone metabolism in human preadipocytes. *Horm Metab Res.* 2002; 34(5):223–8. [PubMed: 12063633]
33. Pasquali R, Casimirri F, Cantobelli S, et al. Effect of obesity and body fat distribution on sex hormones and insulin in men. *Metabolism.* 1991; 40(1):101–4. [PubMed: 1984562]
34. Colangelo LA, Ouyang P, Liu K, et al. Association of endogenous sex hormones with diabetes and impaired fasting glucose in men: multi-ethnic study of atherosclerosis. *Diabetes Care.* 2009; 32(6):1049–51. [PubMed: 19289858]
35. Stellato RK, Feldman HA, Hamdy O, et al. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. *Diabetes Care.* 2000; 23(4):490–4. [PubMed: 10857940]
36. Oh JY, Barrett-Connor E, Wedick NM, et al. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. *Diabetes Care.* 2002; 25(1):55–60. [PubMed: 11772901]
37. Pitteloud N, Hardin M, Dwyer AA, et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. *J Clin Endocrinol Metab.* 2005; 90(5):2636–41. [PubMed: 15713702]
38. Peters JM, Zhou YC, Ram PA, et al. Peroxisome proliferator-activated receptor alpha required for gene induction by dehydroepiandrosterone-3 beta-sulfate. *Mol Pharmacol.* 1996; 50(1):67–74. [PubMed: 8700121]
39. Malkin CJ, Pugh PJ, Jones RD, et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. *J Clin Endocrinol Metab.* 2004; 89(7):3313–8. [PubMed: 15240608]
40. Chen RY, Wittert GA, Andrews GR. Relative androgen deficiency in relation to obesity and metabolic status in older men. *Diabetes Obes Metab.* 2006; 8(4):429–35. [PubMed: 16776750]

41. Tchernof A, Despres JP, Dupont A, et al. Relation of steroid hormones to glucose tolerance and plasma insulin levels in men. Importance of visceral adipose tissue. *Diabetes Care*. 1995; 18(3): 292–9. [PubMed: 7555470]
42. Tchernof A, Labrie F, Belanger A, et al. Androstane-3 α , 17 β -diol glucuronide as a steroid correlate of visceral obesity in men. *J Clin Endocrinol Metab*. 1997; 82(5):1528–34. [PubMed: 9141545]
43. Pritchard J, Despres JP, Gagnon J, et al. Plasma adrenal, gonadal, and conjugated steroids before and after long-term overfeeding in identical twins. *J Clin Endocrinol Metab*. 1998; 83(9):3277–84. [PubMed: 9745441]
44. Pritchard J, Despres JP, Gagnon J, et al. Plasma adrenal, gonadal, and conjugated steroids following long-term exercise-induced negative energy balance in identical twins. *Metabolism*. 1999; 48(9):1120–7. [PubMed: 10484051]
45. Goodman-Gruen D, Barrett-Connor E. Sex hormone-binding globulin and glucose tolerance in postmenopausal women. The Rancho Bernardo Study. *Diabetes Care*. 1997; 20(4):645–9. [PubMed: 9096996]
46. Haffner SM, Katz MS, Dunn JF. Increased upper body and overall adiposity is associated with decreased sex hormone binding globulin in postmenopausal women. *Int J Obes*. 1991; 15(7):471–8. [PubMed: 1894424]
47. Ding EL, Song Y, Manson JE, et al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. *N Engl J Med*. 2009; 361(12):1152–63. [PubMed: 19657112]
48. Plymate SR, Matej LA, Jones RE, et al. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. *J Clin Endocrinol Metab*. 1988; 67(3):460–4. [PubMed: 2842359]
49. Zumoff B, Miller LK, Strain GW. Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone. *Metabolism*. 2003; 52(9):1126–8. [PubMed: 14506617]
50. Strain GW, Zumoff B, Miller LK, et al. Effect of massive weight loss on hypothalamic-pituitary-gonadal function in obese men. *J Clin Endocrinol Metab*. 1988; 66(5):1019–23. [PubMed: 3129444]
51. Vermeulen A, Kaufman JM, Giagulli VA. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. *J Clin Endocrinol Metab*. 1996; 81(5):1821–6. [PubMed: 8626841]
52. Khaw KT, Barrett-Connor E. Endogenous sex hormones, high density lipoprotein cholesterol, and other lipoprotein fractions in men. *Arterioscler Thromb*. 1991; 11(3):489–94. [PubMed: 2029491]
53. Tsai EC, Matsumoto AM, Fujimoto WY, et al. Association of Bioavailable, Free, and Total Testosterone With Insulin Resistance. *Diabetes Care*. 2004; 27(4):861–868. [PubMed: 15047639]
54. Blouin K, Boivin A, Tchernof A. Androgens and body fat distribution. *J Steroid Biochem Mol Biol*. 2008; 108(3–5):272–80. [PubMed: 17945484]
55. Gupta V, Bhasin S, Guo W, et al. Effects of dihydrotestosterone on differentiation and proliferation of human mesenchymal stem cells and preadipocytes. *Mol Cell Endocrinol*. 2008; 296(1–2):32–40. [PubMed: 18801408]
56. Goodpaster BH, Krishnaswami S, Resnick H, et al. Association between regional adipose tissue distribution and both type 2 diabetes and impaired glucose tolerance in elderly men and women. *Diabetes Care*. 2003; 26(2):372–9. [PubMed: 12547865]
57. Gan SK, Samaras K, Thompson CH, et al. Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy. *Diabetes*. 2002; 51(11):3163–9. [PubMed: 12401706]
58. Petersen KF, Shulman GI. Etiology of insulin resistance. *Am J Med*. 2006; 119(5 Suppl 1):S10–6. [PubMed: 16563942]
59. Timmers S, Schrauwen Pandde Vogel J. Muscular diacylglycerol metabolism and insulin resistance. *Physiol Behav*. 2008; 94(2):242–51. [PubMed: 18207474]
60. Vettor R, Milan G, Franzin C, et al. The origin of intermuscular adipose tissue and its pathophysiological implications. *Am J Physiol Endocrinol Metab*. 2009; 297(5):E987–998.

Table 1Selected characteristics of older black men (mean $\pm$ SD)

N	472
Age (years)	72.2 $\pm$ 6.0
BMI (kg/m ²)	26.8 $\pm$ 4.1
Waist circumference (cm)	92.8 $\pm$ 10.4
DXA Total Body Fat (%)	21.7 $\pm$ 5.7
Calf Skeletal Muscle Composition	
Total fat (mm ²)	1819 $\pm$ 890
Subcutaneous fat (mm ²)	1237 $\pm$ 660
Intermuscular fat (mm ²)	402 $\pm$ 420
Skeletal muscle density (mg/cm ³)	78.0 $\pm$ 3.7
Skeletal muscle (mm ²)	6833 $\pm$ 1227
T2DM-related measures	
Glucose (mg/dl)	111 $\pm$ 41
Insulin (μ U/ml)	11.5 $\pm$ 5.4
HOMA-IR	3.2 $\pm$ 2.1
Medical Conditions	
Obese (%)	18.6%
T2DM (%)	32.2%
Serum Sex Steroid Hormones	
SHBG (nmol/L)	53.0 $\pm$ 19.5
DHEA (ng/ml)	1.5 $\pm$ 0.9
DHEA-S (ug/ml)	1.0 $\pm$ 0.6
4-DIONE (ng/ml)	0.6 $\pm$ 0.2
5-DIOL (pg/ml)	607.3 $\pm$ 315.6
T (ng/ml)	4.6 $\pm$ 2.0
Free T (ng/dl)	8.7 $\pm$ 3.25
DHT (pg/ml)	476.5 $\pm$ 245.8
ADT (pg/ml)	177.3 $\pm$ 90.0
ADT-G (ng/ml)	31.7 $\pm$ 17.4
3G (ng/ml)	1.3 $\pm$ 0.9
17G (ng/ml)	2.7 $\pm$ 1.5
E1 (pg/ml)	42.2 $\pm$ 15.5
E2 (pg/ml)	25.1 $\pm$ 9.4

Table 2
Correlation of serum levels of androgens with adiposity and skeletal muscle composition in black men

	SHBG	Androgen Precursors		Bioactive Androgens		Androgen Metabolites				
		4-DIONE	5-DIOL	T	Free T	DHT	ADT	ADTG	3G	17G
BMI (kg/m ²) ¹	-0.42*	-0.14**	-0.14**	-0.35***	-0.21***	-0.37***	-0.20***	0.07	0.07	0.17***
Waist (cm) ¹	-0.41***	-0.13*	-0.15**	-0.38***	-0.25***	-0.36***	-0.18***	0.09	0.13*	0.16***
DXA Total Body Fat (%)	-0.33***	-0.17**	-0.14**	-0.33***	-0.22***	-0.32***	-0.22***	0.07	0.07	0.18***
Total Fat (mm ²) ²	-0.22***	-0.13**	-0.11**	-0.28***	-0.23***	-0.20***	-0.17***	-0.04	-0.03	0.01
Subcutaneous Fat (mm ²) ³	0.06	0.02	0.03	0.01	-0.01	0.08	0.04	-0.11*	-0.15**	-0.14**
Intermuscular Fat (mm ²) ³	-0.08	-0.06	-0.10	-0.18**	-0.14**	-0.15**	-0.08	0.04	0.03	-0.09
Skeletal Muscle Density (mg/cm ³) ⁴	-0.06	0.05	0.02	0.10	0.14*	0.10*	0.14*	0.11	0.03	0.17***
Skeletal Muscle (mm ²) ²	0.10*	-0.05	0.05	-0.06	-0.02	-0.06	-0.16**	-0.01	-0.02	0.04

Values are spearman correlation coefficients

* P<0.05;

** P<0.01;

*** P<0.001

¹ Adjusted for age

² Adjusted for age and height

³ Adjusted for age, height, and DXA total body fat

⁴ Adjusted for age, height, DXA total body fat and pQCT skeletal muscle area

Table 3

The association of serum sex hormone levels with prevalent T2DM in black men

	Age- Adjusted ORs (95%CI)	Age- and BMI- adjusted ORs (95%CI)	Age- and Waist- adjusted ORs (95%CI)	Multivariate ORs (95%CI)
Sex Steroid Hormone				
SHBG (nmol/L)	0.72 (0.57–0.89)	0.77 (0.60–0.98)	0.80 (0.62–1.03)	-
DHEA (ng/ml)	0.98 (0.95–1.00)	0.81 (0.65–1.00)	0.82 (0.66–1.02)	-
DHEA-S (ug/ml)	1.04 (0.85–1.28)	1.05 (0.85–1.29)	1.06 (0.86–1.30)	-
4-DIONE (ng/ml)	0.96 (0.78–1.16)	0.97 (0.80–1.19)	0.98 (0.80–1.20)	-
5-DIOL (pg/ml)	0.72 (0.58–0.89)	0.75 (0.60–0.93)	0.75 (0.60–0.94)	-
T (ng/ml)	0.71 (0.58–0.87)	0.75 (0.60–0.93)	0.77 (0.62–0.96)	-
Free T (ng/dl)	0.77 (0.64–0.94)	0.80 (0.65–0.98)	0.82 (0.66–0.99)	-
DHT (pg/ml)	0.66 (0.53–0.82)	0.69 (0.55–0.87)	0.69 (0.55–0.87)	0.66 (0.52–0.84)
ADT (pg/ml)	0.81 (0.66–0.99)	0.84 (0.68–1.03)	0.84 (0.68–1.03)	-
ADT-G (ng/ml)	1.32 (1.10–1.60)	1.32 (1.08–1.60)	1.32 (1.08–1.60)	-
3G (ng/ml)	1.26 (1.05–1.52)	1.27 (1.05–1.54)	1.27 (1.04–1.53)	1.38 (1.10–1.74)
17G (ng/ml)	1.03 (0.85–1.25)	1.00 (0.82–1.22)	1.00 (0.82–1.22)	-
E1 (pg/ml)	0.93 (0.76–1.13)	0.92 (0.75–1.12)	0.92 (0.75–1.12)	-
E2 (pg/ml)	0.92 (0.75–1.12)	0.91 (0.74–1.11)	0.90 (0.74–1.10)	-
Total and Central Adiposity				
BMI (kg/m ²)	1.27 (1.05–1.54)	N/A	N/A	-
Waist (cm)	1.40 (1.14–1.70)	N/A	N/A	1.61 (1.20–2.10)
DXA Total Body Fat (%)	1.26 (1.03–1.52)	N/A	N/A	-
Skeletal Muscle Composition				
Total fat (mm ²)	1.06 (0.88–1.29)	N/A	N/A	-
Subcutaneous fat (mm ²)	0.90 (0.78–1.00)	0.71 (0.55–0.91)	0.67 (0.53–0.86)	0.68 (0.52–0.88)
Intermuscular fat (mm ²)	1.34 (1.10–1.64)	1.22 (0.97–1.54)	1.18 (0.94–1.49)	-
Skeletal Muscle Density (mg/cm ³)	0.94 (0.74–1.21)	0.97 (0.75–1.25)	1.02 (0.79–1.31)	-
Skeletal Muscle (mm ²)	0.84 (0.68–1.04)	0.75 (0.60–0.94)	0.75 (0.60–0.94)	0.78 (0.61–1.00)

OR, odds ratios; CI, confidence interval; OR is presented for a 1 SD increase in predictor variable. Significant OR are highlighted in bold face font; Logistic regression analysis was used to obtain Model 1 (age-adjusted ORs), Model 2 (age- and BMI- adjusted ORs) and Model 3 (age- and waist-adjusted ORs). Backward regression analysis was used to obtain the multivariate ORs.